缉毒局面临对大麻改期延误的审查,这阻碍了药物发展和患者的获得。 DEA faces scrutiny over delays in marijuana rescheduling, hindering drug development and patient access.

缉毒局官员被指控拖延大麻改期,阻碍MMJ生物制药公司研制大麻素治疗法的工作。 DEA officials have been accused of delaying the rescheduling of marijuana and obstructing MMJ BioPharma's efforts to develop cannabinoid-based treatments. 尽管遵守所有联邦规则,包括林业发展局接受其药物申请,但MMJ没有获得药物管理局为临床试验种植大麻颁发的必要许可证。 Despite following all federal rules, including FDA acceptance of its drug applications, MMJ has not received the necessary DEA license for cannabis cultivation for clinical trials. 这种拖延影响到病人和科学进步,要求监督缉毒局的不当行为和遵守司法部政策的情况。 This delay affects patients and scientific progress, with calls for oversight into DEA misconduct and compliance with DOJ policies.